Acumen Pharmaceuticals Inc（ABOS）财务数据ABOSAcumen Pharmaceuticals Inc

Evaluating the bottom line, Acumen Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -120.50%, provide a clear picture of how effectively ABOS converts its operational activities into shareholder value.

In the context of the broader market, ABOS competes directly with industry leaders such as CRBP and DERM. With a market capitalization of $193.09M, it holds a significant position in the sector. When comparing efficiency, ABOS's gross margin of N/A stands against CRBP's N/A and DERM's 61.58%. Such benchmarking helps identify whether Acumen Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Acumen Pharmaceuticals has reported a reduced net loss of $32.72 million for Q2 2026, down from $40.95 million in the same quarter last year, indicating improved cost management. The company also has strong cash reserves of $110.2 million, which supports ongoing operations and R&D.